Cyclo Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
March 23 2022 - 8:25AM
Business Wire
- Live webcast fireside chat on Wednesday,
March 30th at 12:30 PM ET
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or
the “Company”), a clinical stage biotechnology company dedicated to
developing life-changing medicines through science and innovation
for patients and families living with diseases, today announced
that members of the Cyclo Therapeutics management team will
participate at the 2022 Virtual Growth Conference presented by
Maxim Group LLC and hosted by M-Vest, taking place March 28-30,
2022.
In addition to the Company’s corporate presentation available on
demand for registered attendees, N. Scott Fine, Chief Executive
Officer and Lise Lund Kjems, MD, PhD, Chief Medical Officer of
Cyclo Therapeutics will participate in a live fireside chat
moderated by Jason McCarthy, PhD, Head of Biotechnology Research at
Maxim Group, on Wednesday, March 30, 2022, at 12:30 PM ET.
During this virtual conference, investors will hear from
executives from a wide range of sectors including Biotech, Clean
Energy, Electric Vehicles, Financial Services, Fintech & REITs,
Gaming & Entertainment, Healthcare, Healthcare IT,
Infrastructure, Shipping and Technology/ Media/Telecom. The
conference will feature company presentations, fireside chats,
roundtable discussions, and live Q&A with CEOs moderated by
Maxim Research Analysts.
This conference will be live on M-Vest. To attend, just sign up
to become an M-Vest member.
Click Here to Reserve Your Seat
About Cyclo Therapeutics
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology
company dedicated to developing life-changing medicines through
science and innovation for patients and families suffering from
disease. The Company’s Trappsol® Cyclo™, an orphan drug designated
product in the United States and Europe, is the subject of four
formal clinical trials for Niemann-Pick Disease Type C, a rare and
fatal genetic disease, (www.ClinicalTrials.gov NCT02939547,
NCT02912793, NCT03893071 and NCT04860960). The Company is planning
an early phase clinical trial using Trappsol® Cyclo™ intravenously
in Alzheimer’s Disease based on encouraging data from an Expanded
Access program for late-onset Alzheimer’s Disease (NCT03624842).
Additional indications for the active ingredient in Trappsol®
Cyclo™ are in development. For additional information, visit the
Company’s website: www.cyclotherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220323005564/en/
JTC Team, LLC Jenene Thomas (833) 475-8247 CYTH@jtcir.com
Cyclo Therapeutics (NASDAQ:CYTH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyclo Therapeutics (NASDAQ:CYTH)
Historical Stock Chart
From Apr 2023 to Apr 2024